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Abstract
Background Despite rehabilitation being increasingly advocated for people living with incurable cancer, there is
limited evidence supporting efficacy or component parts. The progressive decline in function and nutritional in this
population would support an approach that targets these factors. This trial aimed to assess the feasibility of an exercise
and nutrition based rehabilitation programme in people with incurable cancer.
Methods We randomized community dwelling adults with incurable cancer to either a personalized exercise and
nutrition based programme (experimental arm) or standard care (control arm) for 8 weeks. Endpoints included
feasibility, quality of life, physical activity (step count), and body weight. Qualitative and health economic analyses
were also included.
Results Forty-five patients were recruited (23 experimental arm, 22 control arm). There were 26 men (58%), and the
median age was 78 years (IQR 69–84). At baseline, the median BMI was 26 kg/m2 (IQR: 22–29), and median weight
loss in the previous 6 months was 5% (IQR: 12% to 0%). Adherence to the experimental arm was >80% in 16/21
(76%) patients. There was no statistically significant difference in the following between trial arms: step
count  median % change from baseline to endpoint, per trial arm (experimental 18.5% [IQR: 61 to 65], control
5% [IQR: 32 to 50], P = 0.548); weight  median % change from baseline to endpoint, per trial arm (experimental
1%[IQR: 3 to 3], control 0.5% [IQR: 3 to 1], P = 0.184); overall quality of life  median % change from baseline
to endpoint, per trial arm (experimental 0% [IQR: 20 to 19], control 0% [IQR: 23 to 33], P = 0.846). Qualitative
findings observed themes of capability, opportunity, and motivation amongst patients in the experimental arm. The
mean incremental cost of the experimental arm versus control was £-319.51 [CI 7593.53 to 6581.91], suggesting
the experimental arm was less costly.
Conclusions An exercise and nutritional rehabilitation intervention is feasible and has potential benefits for people
with incurable cancer. A larger trial is now warranted to test the efficacy of this approach.
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Introduction
Cancer is becoming more common, yet advances in treat-
ment mean that more people are living longer with incurable
disease than ever before.1 Indeed the number of people liv-
ing with cancer is increasing by approximately 3% every year
with life expectancies of several months to years.2 Further,
with population aging, people with incurable cancer are in-
creasingly older, living longer, and have more co-morbidities.
Langbaum and Smith argue that ‘many people with cancer
function fully for years, and it is commonplace for patients
with chronic cancer to face the challenge of determining
how to optimize their remaining time’.1 This view is being
increasingly acknowledged by learned societies with the
European Society of Medical Oncology (ESMO)3 and
American Society of Clinical Oncology (ASCO),4 supporting re-
habilitation as a key component of cancer care. Optimizing
overall function has been purported to improve quality of
life, tolerability of cancer therapies and reduce patient and
caregiver distress. Furthermore, this may have positive bene-
fits on health care resource allocation and use. Although
these are laudable achievements there remains a paucity of
evidence to directly support the benefits of rehabilitation in
patients with incurable cancer and to guide the constituent
parts of programmes.
It would seem logical that targeting physical and
nutritional deficits should be the cornerstones of any rehabil-
itation intervention. Together, deterioration in physical func-
tion combined with loss of muscle and fat termed ‘cancer
cachexia’, result in approximately 50% of cancer deaths, and
becomes more prevalent as disease progresses. It has been
advocated that to optimally address cachexia, any interven-
tions should be multimodal and comprise nutritional support
and exercise advice.5–8 However, to date, there is limited ev-
idence to support this.
Therefore, a trial was undertaken to assess the feasibility
of an exercise and nutritional rehabilitation programme in
people with incurable cancer. Termed the ENeRgy trial, this
was a randomized, feasibility trial of an Exercise and
Nutrition-based Rehabilitation programme (ENeRgy) versus
standard care in people with cancer.
Methods
Study design and patients
We undertook a randomized, open label, feasibility trial at a
specialist palliative care unit in the UK, serving a geographi-
cally defined population of approximately one million.
Eligible patients met the following criteria: outpatients; age
≥18 years; Karnofsky performance status (KPS) ≥ 60; diagno-
sis of incurable cancer (defined as metastatic or locally
advanced cancer not amenable to curative treatment); not
undergoing anti-cancer therapy (hormonal treatment and/
or bisphosphonates were permitted); a clinician predicted
survival of >3 months.
Patients undergoing anti-cancer therapy (hormonal,
bisphosphonates permitted), receiving parenteral nutritional
support, who had dysphagia or who were co-enrolled in a
clinical trial were excluded. Those who had received any sys-
temic anti-cancer therapy in the preceding 4 weeks were
not eligible.
The trial was conducted as per Good Clinical Practice and
the Declaration of Helsinki. The protocol was approved by
an ethics committee for human research (ethics reference:
17/WS/0226). All patients provided written informed con-
sent. The authors certify that they comply with the ethical
guidelines for authorship and publishing of the Journal of
Cachexia, Sarcopenia and Muscle.9 The trial was registered
at ClinicalTrials.gov: NCT03316157. The rationale and trial de-
sign have been previously described.10
Randomization
Patients were randomized centrally in a 1:1 ratio of experi-
mental to control, using a block randomization with random
block sizes and stratified for baseline KPS (60–80% or 90–
100%).
Procedures
The experimental arm was an exercise and nutrition-based
rehabilitation programme. Following baseline assessments
and randomization, patients had an interview with the trial
physiotherapist and dietitian. Based on this interview, they
were given personalized advice on nutrition and exercise.
The exercise component, developed by the physiothera-
pist, was a home-based programme consisting of aerobic
and resistance training in divided intervals as per patient
choice and capability. The aerobic component totalled
60 min of exercise per week (e.g. walking) at moderate inten-
sity (warm and slightly out of breath—modified Borg scale 3–4
rating). The resistance component focussed on major muscle
groups in the upper and lower body, predominantly using
body weight exercises including standing press ups, half
squats and shoulder thrusts, with sets advised three times
per week.
The nutrition component aimed to ensure optimal
nutritional intake and consisted of dietitian-led counselling
(personalized for each patient) taking into account dietary
preferences. Patients were also supplied with an Oral Nutri-
tional Supplement (ONS—ProSure®—Abbott Laboratories,
ILL, USA) and advised to take two per day. Each 220 mL sup-
plement contained 1 g of eicosapentaenoic acid (EPA) and
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1.5 kcal/mL. Patients who did not tolerate the ONS due to
preference were offered an alternative ONS and oral capsules
containing 2 g EPA.
Written information supporting the exercise and nutrition
interventions were provided (Supporting Information,
Data S3). The dietitian and physiotherapist reviewed
adherence to the relevant interventions during weekly clinic
attendances by patients. At this time, progress was reviewed
and the intervention modified if needed, to support
adherence. A patient diary (paper) was used to record the
number of minutes of aerobic exercise per day, the number
of strength exercises performed per day, and the number of
nutritional supplements taken per day, and this was
discussed with the patient at their weekly visits.
Patients randomized to the control arm received their
usual care which may have included ongoing specialist pallia-
tive care follow-up as per individual patient need. They were
entitled to any additional support from allied health profes-
sionals if needed. Those in the control arm received weekly
telephone calls from the research team to ensure adherence
to trial-related data collection and record any nutritional in-
terventions (dietitian and/or prescribed ONS) and exercise
undertaken. These data were collected to assess any contam-
ination of the control group (mimicking any aspect of the
trial-related intervention). Patients in the control arm were
offered the trial intervention at the end of their involvement
in the trial.
Endpoints
The primary endpoint of the trial was to assess feasibility of
the experimental arm (rehabilitation programme). Feasibility
was assessed primarily by adherence to the intervention
using the prescribed number of exercises/ONS prescribed
versus actual undertaken. We recorded adherence by using
the prescribed versus actual amounts of exercise and nutri-
tional supplements performed/taken. These data were ob-
tained from patient recorded diaries (of which completion
was supported by weekly telephone calls by research staff).
Secondary endpoints assessed other aspects of feasibility
using recruitment rate (could we recruit our target sample
within an acceptable time frame [18 months]), attrition rate
(compared with similar studies in patients with advanced
cancer), and contamination of the control arm (use of ONS
outside the trial and exercise uptake). The acceptable attri-
tion rate was defined as<44%, and this was informed by pre-
vious work in palliative and supportive care trials.11
The exploratory endpoints examined the following.
Physical function was assessed using a physical activity
monitor (Fitbit®, San Francisco, USA). Patients wore this
pre-randomization for 7 days then at the end of the trial for
7 days. We assessed mean daily step count at these time
points. We also assessed physical function assessed using
the timed up and go (TUG) test,12 2 min walk test (TMWT),13
and the Life Space Assessment (LSA) questionnaire.14 All of
these were carried out at baseline (pre-randomization) and
at the trial endpoint.
Performance status was assessed at baseline using
Karnofsky performance status criteria.15 Nutritional status
was assessed using the abridged Patient Generated Subjec-
tive Global Assessment (abPG-SGA),16 body weight, and as-
sessment of nutritional intake using a 10-point scale (AveS).17
Quality of life was assessed using the European Organisa-
tion for the Research and Treatment of Cancer Quality of Life
Questionnaire – C15PAL (EORTC QLQ-C15PAL),18 the EQ-5DL,
and the EQ-VAS questionnaires.19
Quality of sleep was assessed using sleep data recorded by
the physical activity monitor. Adverse events were also
assessed and reported.
Health economic endpoints examined the potential impact
on patient-reported health utility, healthcare-related re-
source use and costs. Health utility was assessed by the EQ-
5D-5L20 and EQ-VAS patient completed questionnaire,
healthcare utilization, and out of pocket expenses.19 Ques-
tionnaires were designed to measure health-related utility
healthcare-related resource use and costs, administered at
baseline and follow-up assessment time-points. Patient
health-related quality of life was captured using a patient re-
ported outcome measure; the EQ-5D-5L and EQ-VAS ques-
tionnaires. Utility values were assigned to responses using
the standard UK value set.21 Healthcare utilization and costs
were collected using a bespoke patient completed question-
naire, adapted from the UK Cancer Costs Questionnaire [cita-
tion: https://blogs.ed.ac.uk/ukcc/].
Unit costs were assigned to resource use items using stan-
dard national costing sources such as PSSRU22 and NHS refer-
ence costs,23 or through consultation with relevant service
business managers. Costs were summarized from the per-
spectives of the NHS, the charitable and 3rd sector and the
patient and their carers. Cost-effectiveness was calculated
as the Incremental Cost-effectiveness Ratio (ICER), expressed
as cost per QALY gained.
A within-trial cost effectiveness analysis was performed in
accordance with the methodological specification of the NICE
Guide to the Methods for Health Technology Assessment.24
Uncertainty was evaluated using probabilistic sensitivity anal-
ysis (PSA) and value of information (VoI) analysis, imple-
mented using the bootstrap method (1000 replications). For
the PSA and for the VoI Analysis, the SAVI Tool from the
University of Sheffield was used.25
Statistical considerations
As the primary endpoint of this study was to assess the feasi-
bility of the trial, rather than superiority of the experimental
arm over the control arm, a formal sample size calculation
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was not necessary.26 Our justification for the sample size of
40 patients was supported by our previous work,6 our poten-
tial pool of eligible patients (estimated at 1300 per year), con-
sensus in the sample size of feasibility trials,27 and based on
this, we estimated we would be able to express the percent-
age completing the study protocol to within ±9% assuming a
two-sided 95% confidence interval (CI) around an expected
percentage of 90% completion. Findings are presented
descriptively split by trial arm and endpoints (e.g. change in
daily step count and change in weight) are compared be-
tween trial arms using appropriate non-parametric tests
(Mann–Whitney U test). No interim analysis was planned or
undertaken. The analysis was performed using data from on
all patients recruited. SPSS v23 (Chicago, IL, USA) was used.
Embedded qualitative study
Interviews with a purposive sample of experimental arm pa-
tients were audio-recorded and transcribed verbatim. Coding
of all transcribed data, conducted by two researchers blind to
the trial results (A. L. and J. H.), was inductive and focused on
the questions: ‘What is the experience of ENeRgy?’ and
‘What are the barriers to and facilitators of the physical activ-
ity and nutritional components of ENeRgy?’
The analysis used the framework technique,28 which in-
volves systematic and interconnected stages of sifting and
charting coded qualitative data, then mapping patterns in a
search for understanding and explanation. The pre-existing
Figure 1 Trial profile.
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framework, Capability, Opportunity, and Motivation together
result in Behaviour (COM-B) was applied to the coded data.
Coded data extracts were categorized (J. H.) as capability, op-
portunity, or motivation for physical activity or for nutritional
intake. Data relevant to understanding the experience of and
engagement with ENeRgy but falling outside the COM-B
framework were also captured in a visual representation of
the whole data set. Overarching patterns were identified that
revealed factors influencing adherence/non-adherence to
ENeRgy.
The trial was sponsored jointly by the University of Edin-
burgh and NHS Lothian.
Role of the funding source
This trial was funded by a grant from Marie Curie and the
Chief Scientist Office (Scotland, UK). The oral nutritional sup-
plement was provided free of charge by Abbott Laboratories.
The funders and Abbott Laboratories had no involvement in
the design, conduct or analysis of the trial. B. L., C. H.,
M. F., P. H., K. D., E. W., A. L., J. H., and C. G. had access to
raw data. The corresponding author had final responsibility
for the decision to submit the manuscript for publication.
Results
From 30 January 2018 to 24 April 2019 (15 months), 45 pa-
tients were recruited (23 experimental arm, 22 control arm)
(Figure 1). Baseline characteristics are shown in Table 1.
The median age was 78 years (IQR: 69–84) and 26 (58%) were
male. The most common primary cancer site was gastrointes-
tinal (18 [40%]), and patients had either metastatic (29 [64%])
or loco-regionally advanced disease (16 [36%]). Twenty-nine
(65%) of patients had a Karnofsky performance score of 60–
80. The median BMI at baseline was 26 kg/m2 (IQR: 22–29),
and the median weight loss in the previous 6 months was
5% (IQR: 12%–0%) (Figure 2).
Table 2 details the primary endpoints of feasibility of the
experimental arm (rehabilitation programme) assessed by ad-
herence to the prescribed exercises/ONS versus actual under-
taken. For the experimental arm, adherence was defined as
excellent if this was ≥80%, good if this was 50–79% and poor
if this was below 50%. For individual components of the ex-
perimental arm, excellent adherence was achieved by at least
16/21 (76%) of patients, and for adherence to all compo-
nents, this was either good (8 [38%]) or excellent (12 [57%])
patients. Therefore, feasibility in terms of compliance to the
experimental interventions was acceptable, and the trial
was positive in this regard.
Secondary endpoints assessed other aspects of feasibility.
The recruitment target was 40 patients over 18 months; how-
ever, accrual was better than expected, and 45 patients were
recruited over 15 months, and then, recruitment was
stopped. Of the 121 people screened, 29 were not eligible
and were not assessed further. Of the remaining 92 who were
further assessed for participation, 45 (49%) were recruited, 9
(10%) were ineligible, 32 (35%) declined, 1 (1%) was not re-
cruited due to an investigator decision, and 5 (5%) for other
reasons. The recruitment rate was 37% (45/121) which was
similar to other trials in this patient population.29,30 The main
reason for patients not participating was that they declined
(32 [35%]).
Of the 45 patients recruited, 29 (64%) completed the trial
resulting in an attrition rate of 36% (16/45). The attrition rate
was 30% (7/23) and 41% (9/22) in the experimental and con-
trol arms respectively. The most common reason for attrition
was deteriorating health (four patients—experimental; seven
patients—control arm).
Contamination in the control arm was low; one patient in
the control arm started an ONS and another increased their
pre-trial ONS use. Patients in the control arm did not have





n % n %
Age <55 6 26 2 9
/55–65/ /3 /13/ /4 /18/
>65 /14 61 /16 73
Male gender 14 61 12 55
Primary cancer
Gastrointestinal 12 52 6 27
Thoracic 1 4 2 9
Breast 2 9 4 18
Urological/Gyn 4 17 6 27
Myeloma 2 9 3 14
Head and neck 1 4 0 0
Other: (Endocrine)1 4 1 5
Cancer stage
Loco-regionally 8 35 8 36
Metastatic 15 65 14 64
Current cancer treatment
Hormonal 5 22 7 32
Bisphosphonate 2 9 2 9
Steroids 6 26 7 32
Performance status
60–80% 15 65 14 64
90–100% 8 35 8 36
Body mass index
<18.5 4 17 2 9
18.5–25 9 39 6 27
25.1–30 7 30 9 41
>30.1 3 13 5 23
Weight change at baseline(<1 month)
Weight gained 4 17 3 14
Loss 0–5% 18 78 14 64
Loss >5% 0 0 5 23
Unknown 1 4 0 0
Weight change at baseline (<6 months)
Weight gained 2 9 2 9
Loss 0–5% 10 43 5 23
Loss >5% 7 30 9 41
Unknown 4 17 6 27
Exercise and nutrition RCT in cancer 5
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12806
increased exercise based on self-reported measures and activ-
ity data.
Table 3 details the exploratory endpoints examining physi-
cal function, weight, and nutrition, assessed as part of the
trial. There was no evidence of statistically significant differ-
ences in the % difference in daily step count (P = 0.548), timed
up and go test (P = 0.767), 2-min walk test (P = 0.484), and life
space assessment (P = 1.00) between the trial arms. Patients
in the experimental arm gained a median of 1% (IQR: 3%
to 3%) of weight versus those in the control arm who lost a
median of 0.48% (IQR: 2.6% to 0.64%), P = 0.184.
Table 4 details the exploratory endpoints examining pa-
tient reported outcomes of quality of life measured using
the EORTC QLQ-C15 PAL. With the exception of emotional
functioning (P = 0.006), there were no statistically signifi-
cant differences between the trial arms. There was no dif-
ference in carer-related quality of life (P = 0.5) or any
sleep parameters between the trial arms—data not
presented).
Table 5 details adverse events. There were no SAEs for
patients in the trial. There were 39 AEs recorded in total,
20 in the experimental arm (51%), and 19 in the control
arm (49%). Of AEs in the experimental arm, nine (45%) were
related to the ONS, nine (45%) related to the underlying
cancer diagnosis, and two (10%) were due to non-cancer-re-
lated issues.
Figure 2 Trial schematic.
Table 2 Primary endpoint: adherence to the experimental arm
Adherence to individual intervention components (n = 21)a
<50% ≥50–79% ≥80%
n (%) n (%) n (%)
Oral nutritional supplement (n = 21) 1 (5) 4 (19) 16 (76)
Resistance (n = 21) 1 (5) 3 (14) 17 (81)
Aerobic (n = 21) 1 (5) 2 (10) 18 (86)
Adherence to combined intervention components <50% ≥50% ≥80%
Aerobic Resistance 1 (5) 4 (19) 16 (76)
Aerobic ONS 1 (5) 6 (29) 14 (67)
Resistance ONS 1 (5) 7 (33) 13 (62)
Aerobic Resistance ONS 1 (5) 8 (38) 12 (57)
aTwo patients withdrew from the trial post randomization.
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In the control arm, there were 12 cancer-related AEs
(63%) and seven unrelated AEs (37%), relating to
pre-existing medical conditions or not serious enough to
constitute an SAE.
Health economic results
Supporting Information, Data S1 contains the full health eco-
nomic analysis results. In summary, the main drivers of costs
were hospital inpatient stays and unscheduled hospice stays
followed by community care, outpatient appointments, out
of hours (OOH) services, and travel costs. The mean incre-
mental cost of the experimental arm versus control is
£-319.51 [CI 7593.53 to 6581.91], suggesting the experi-
mental arm is less costly. The mean incremental benefit of
the experimental arm versus control was 0.00018 QALYs [CI
0.021, 0.023]. Probabilities of the intervention being cost
saving and more beneficial compared with the control group
were 0.544 and 0.517, respectively.
Qualitative analysis
Fourteen patients in the experimental arm had an end of trial
interview. The factors influencing capability, opportunity, and
motivation to adhere to ENeRgy with supporting evidence
(patient quotes) are reported in the Supporting Information,
Data S2.
In summary, to engage with ENeRgy patients had to per-
ceive benefit; improvement in energy levels, increased phys-
ical or social activity, improved food intake, weight gain or, for
one patient, an expectation of improved survival. For 10 of
the patients, ENeRgy was enjoyable and restorative. How-
ever, only some of these patients reported improvement in
activity, physical strength, oral intake, or weight. Perception
of benefit, such as a sense of achievement, knowing what
to do, a sense of control, or hope of improvement, could mo-
tivate adherence. Family members and carers also influenced
ability to and willingness to adhere to ENeRgy. The four pa-
tients who did not report benefit ranged from mildly resistant
to non-adherent. These patients revealed that ENeRgy can
have an unintended consequence of raising awareness of
progressing disease and impending death.
Table 3 Exploratory endpoints examining physical function, weight, and nutrition
Experimental arm Control arm
PN Median (IQR) n Median (IQR)
Daily step counta Baseline 22 2954 (2168–4143) 22 2294 (591–3821)
Endpoint 16 2898 (1055–5005) 12 2478 (727–3645)
Difference 15 476 (1592–1882) 12 6 (860–335)
Difference % 15 19 (61 to 65) 12 5 (32 to 50) 0.548*
Timed up-and go test (s) Baseline 23 13 (11–17) 22 16 (11–24)
Midpoint 17 15 (12–18) 15 14 (11–27)
Endpoint 16 14 (12–21.8) 12 15 (12–23)
Difference 16 0.5 (3–4) 12 0.5 (1–2)
Difference % 16 5 (18–20) 12 4.5 (3–12) 0.767*
2 min walk test (m) Baseline 23 114 (76–144) 21 104 (66–122)
Midpoint 17 115 (77–136) 13 107 (52–137)
Endpoint 16 116 (75–138) 10 106 (68–122)
Difference 16 9 (5–18) 10 2 (10–12)
Difference % 16 6 (4–27) 10 2 (10–15) 0.484*
Life space assessment (max score 120) Baseline 21 53 (32–81) 22 37(31–52)
Midpoint 18 38 (34–60) 16 52 (32–66)
Endpoint 16 50 (35–64) 13 48 (34–58)
Difference 16 0 (16–11) 13 2 (10–5)
Difference % 16 0 (21–41) 13 5 (19–17) 1.00*
Weight Baseline 23 71 (60–79) 22 70.8 (62–86)
Midpoint 17 76 (63–85) 15 68 (61–89)
Endpoint 16 80 (62–88) 13 67(57–87)
Difference 16 1 (2–2) 13 3 (2–0)
Difference % 16 1 (3–3) 13 0.5 (3–1) 0.184*
aPG-SGA score (0–36) Baseline 23 4 (1–9) 22 6 (2–11)
Midpoint 18 5 (1–16) 15 6 (1–14)
Endpoint 16 8 (1–13) 13 6 (1–10)
Difference 16 1 (2–5) 13 1 (3–3)
Difference % 16 27 (18–300) 13 42 (73–117) 0.249*
AveS score (0–10) Baseline 23 8 (5–8) 22 7 (5–8)
Midpoint 18 7 (5–9) 16 8 (6–10)
Endpoint 16 7 (4–10) 13 8 (7–10)
Difference 16 0 (1–1) 13 0 (2–2)
Difference % 16 0 (25–22) 13 0 (16–31) 0.398*
*Mann–Whitney U-test.
aFull 24 h periods.
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Discussion
Our findings demonstrate that delivering and testing a reha-
bilitation programme incorporating exercise and nutritional
advice/supplementation, delivered in an outpatient setting
to people with incurable cancer, is feasible. This trial re-
cruited ahead of schedule and target, with an acceptable at-
trition rate in the setting of advanced cancer. The trial was
not powered to assess the effects on nutritional, functional
or quality of life outcomes, but encouraging changes in emo-
tional functioning were observed, echoed by our qualitative
findings. Our health economic analyses were also encourag-
ing. There is a strong belief that rehabilitation should be an
optional therapy for the management of people living with
incurable cancer, yet trials supporting this viewpoint are
scarce. The present trial provides a foundation for larger trials
to assess the efficacy of such an approach.
There is limited similar research for comparison; however,
two studies are notable. Naito and co-workers completed a
single arm trial examining a multimodal intervention
(exercise and nutrition) in 30 elderly patients with lung or
pancreatic cancer (NEXTAC-ONE).30 They demonstrated
feasibility, and a randomized phase two trial is underway to
further assess this approach.31 Edbrooke and co-workers un-
dertook a randomized trial assessing exercise and behav-
ioural change strategies in 92 patients with inoperable lung
cancer.32 No improvement in exercise capacity was observed
(primary outcome), but quality of life improved. These trials,
along with the present trial, are well aligned with recommen-
dations by ESMO,3 ASCO,4 and the UK National Institute for
Clinical Excellence (NICE) for the care of people with incur-
able cancer. However, a rehabilitative approach, integrated
into routine care, remains the exception rather than the
norm. In the present study, the paradigm and design were in-
formed by our previous work in cancer cachexia where the
importance of a multimodal approach including exercise
and optimal nutrition is advocated. Cancer cachexia remains
the cause of death in approximately half of patients with can-
cer, and the combination of nutritional and functional deficits
acts synergistically with devastating consequences. Previous
work has focussed on uni-modal exercise approaches to reha-
bilitation with scarce attention to nutritional care scarce. Op-
timizing nutritional care alongside physical function may
serve to optimize rehabilitative potential but also address ca-
chexia as exercise itself has an anti-inflammatory effect. It is
hoped that future work will elucidate this.
A key strength of our trial is the embedded qualitative
analysis. Feasibility trials often do not progress to efficacy tri-
als due to a lack of encouraging effects on exploratory end-
points, and as such, interventions may seem ineffective.
However, we would argue that in feasibility trials, with mod-
est sample sizes, it is unrealistic to expect a plethora of en-
couraging exploratory endpoint results. Richards and
colleagues argue that ‘Applying mixed methods integration
techniques to data or findings from studies involving both
RCTs and qualitative research can yield insights that might
be useful for understanding variation in outcomes, the
Table 5 Adverse events
AE type Experimental arm (n = 23) Control arm (n = 22)
AE relating to ONS
Description
9
- Flatus/gurgling from stoma
- Flatulence/stool frequency
- Flatulence/gurgling from bowel










- Chest infection ×2
- Sub-hepatic haematoma
- Intrahepatic bleed
- Oesophageal bolus obstruction (tablet)
- Falls (recurrent)
- Admission to hospice-reduced mobility
- Duodenal obstruction
12
- Deep vein thrombosis
- Hypercalcaemia
- Fall ×3
- Chest infection ×2
- Delirium
- Rectal bleeding
- Pathological femur fracture
- Pressure sore
- Dysphagia
AE unrelated to cancer
Description
2
- Urinary tract infection
- Diarrhoea and vomiting
7
- Tooth abscess
- Atrial fibrillation ×2
- Cardiovascular complication
- Diarrhoea
- Oral antibiotics for skin wound
- Diarrhoea and vomiting
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mechanism by which interventions have an impact, and iden-
tifying ways of tailoring therapy to patient preference and
type’, and we agree.33 The qualitative findings demonstrated
the positive impact of the intervention and suggest continua-
tion to a larger trial is worthwhile and will help refine aspects
of the trial design. There are limited qualitative studies con-
ducted as part of quantitative clinical trials in cancer rehabil-
itation; however, Edbrooke and co-workers are to be
commended for assessing the patient experience of their ex-
ercise intervention,34 as part of their clinical trial.32
The Health Economic Analysis undertaken suggested that
the rehabilitation intervention was cost-saving compared with
the control group. We focussed on the costs to the NHS, and
community care with some indication of costs to the patients
such as travel costs. One potential reason for the cost saving
was that the care provided replaced or prevented community
healthcare needs. It may have been due to patients having ad-
ditional attention to their wider symptom control needs (e.g.
pain management) or indirect psychological support from
the trial team. The Health Economic Analysis is an important
part as even if a rehabilitation intervention proves to be effi-
cacious, excess costs may prohibit wide spread integration
into health care. Cost-effectiveness analyses may therefore
support widespread integration.
The trial had several limitations including the sample size.
This was small however in terms of a feasibility trial it was rea-
sonable; however, any definitive conclusions on efficacy can-
not be drawn. Further the sample size was also
underpowered for health economic analysis, particularly for
estimation of costs and this will need further evaluated in
any larger trial. We also acknowledge that the heterogeneous
sample (age, tumour type, etc.) is a limitation. It was also dif-
ficult to standardize background care to ensure both arms re-
ceived similar care with the exception of the rehabilitation
intervention. This latter point is key, and we cannot rule out
that improvements in emotional functioning seen in the inter-
vention arm were as result of contact with trial staff rather
than the intervention per se. Such aspects are difficult to dis-
entangle yet represent key considerations in future trial de-
sign. We also acknowledge that while the intervention
targeted physical function and nutrition, we did not quantify
degree of cancer cachexia or incorporate specific measures
of body composition (lean mass assessment) or measures of
muscle function (e.g. hand grip strength). Rather, we focussed
on generic measures of function (physical activity) and quality
of life but accept that the former parameters would be of in-
terest. Further, characterizing cachexia stage of participants at
enrolment, in future trials, would be of interest.
Conclusion
A rehabilitation intervention targeting exercise and nutri-
tion, in people with incurable cancer, is feasible and has
potential benefits in terms of emotional function, motiva-
tion, capability attitudes, and costs. The trial was feasible
and provides sufficient support for progression to a larger
trial to assess efficacy. Such a trial, ENeRgise, is in develop-
ment and, along with similar trials, will serve to inform
rehabilitation interventions in people living with incurable
cancer.
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